Searched for
PHARMACEUTICAL CONSOLIDATION EUROPE
For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...- ETMarkets PMS Talk | We analyse over 300 data points to identify alpha: Wright PMS' Sonam SrivastavaWright PMS's Sonam Srivastava champions a data-driven approach to active investing, analyzing over 300 data points to identify alpha. Her f...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Assam CM Himanta Biswa Sarma meets 'Team Europe' delegation to boost trade, investment linkagesAssam Chief Minister Himanta Biswa Sarma met the "Team Europe" EU delegation to boost trade and investment. The two-day visit focuses on se...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Anupam Rasayan to acquire up to 43 pc stake in Bliss GVS Pharma for around Rs 1,369 crSpecialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with a...
- Want to jump into the 'China is back' rally? Tread carefullyInvestors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...
- Stocks in news: Adani Enterprises, Tata Motors PV, Tata Steel, Jio Financial, ITC HotelsMarkets extended their rebound for a second consecutive session on Thursday, buoyed by supportive global cues and selective buying in heavy...
- Why market rose today? Sensex rises 790 points, Nifty closes near 23,700. 5 key drivers behind surgeIndian stock markets are experiencing a significant rally. The BSE Sensex and Nifty 50 indices have climbed over 1 percent each. This surge...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Organon gives Sun Pharma scale and reach, but challenge lies in integration, executionSun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It ...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Granules India Q2 Results: Profit jumps 80% boosted by Paracetamol salesThe company said 51% of its revenue came from finished dosages, which is its biggest business. Active pharmaceuticals ingredients and pharm...
- Glenmark Q3 profit up 11% to Rs 116 croreConsolidated revenue stood at Rs 2,555.04 crore against Rs 2,203.66 crore in the year-ago period.
- Glenmark Q2 net down 4.23% at Rs 214.12 crThe company had posted a net profit of Rs 223.58 crore for the corresponding period of the previous fiscal, Glenmark Pharmaceuticals said i...
- Glenmark Pharmaceuticals reports Q4 net profit at Rs 10.61 croreGlenmark Pharmaceuticals reported a consolidated net profit of Rs 10.61 crore for the fourth quarter ended March 31, 2015.
Load More
